Diagnostic Performance of Chest CT for SARS-CoV-2 Infection in Individuals with or without COVID-19 Symptoms
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.05.18.20097444: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the AZ Delta Institutional Review Board with a waiver of informed consent from study participants considering the study is based on secondary analysis of existing data (Clinical Trial Number: B1172020000008) Procedures: On admission all subjects received a chest CT (detailed scanning protocol in Online supplement) with structured reporting by consensus evaluation of various indicators: temporal disease stage 1 to 3 of viral pneumonia, the extent of lung involvement by estimated residual aerated lung tissue on a scale of 1 to 5 in the 5 lobes and CO-RADS (COVID-19 Reporting and Data Systems).
Consent: The study was approved by the …SciScore for 10.1101/2020.05.18.20097444: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the AZ Delta Institutional Review Board with a waiver of informed consent from study participants considering the study is based on secondary analysis of existing data (Clinical Trial Number: B1172020000008) Procedures: On admission all subjects received a chest CT (detailed scanning protocol in Online supplement) with structured reporting by consensus evaluation of various indicators: temporal disease stage 1 to 3 of viral pneumonia, the extent of lung involvement by estimated residual aerated lung tissue on a scale of 1 to 5 in the 5 lobes and CO-RADS (COVID-19 Reporting and Data Systems).
Consent: The study was approved by the AZ Delta Institutional Review Board with a waiver of informed consent from study participants considering the study is based on secondary analysis of existing data (Clinical Trial Number: B1172020000008) Procedures: On admission all subjects received a chest CT (detailed scanning protocol in Online supplement) with structured reporting by consensus evaluation of various indicators: temporal disease stage 1 to 3 of viral pneumonia, the extent of lung involvement by estimated residual aerated lung tissue on a scale of 1 to 5 in the 5 lobes and CO-RADS (COVID-19 Reporting and Data Systems).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analyses were performed using MedCalc (version 12.2.1, Belgium) and considered significant if P value was less than .05. MedCalcsuggested: (MedCalc, RRID:SCR_015044)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The main limitation of our study is that it was conducted in the pandemic phase of SARS-CoV-2 infection, in a time frame with low prevalence of other respiratory viral infections such as influenza that can induce similar radiological abnormalities. In the influenza season, the diagnostic power of CORADS 5 for SARS-CoV-2 infection will decrease. In clinical practice, however, this does not argue against its medical utility, since a CO-RADS score of 5 is always an informative finding that should trigger targeted reflex testing for respiratory pathogens and differentiation between infectious versus non-infectious inflammatory conditions. In addition to its diagnostic value, chest CT is evidently also useful to assess the overall severity of pulmonary involvement (number of affected lobes and residual amount of well-aerated functional tissue) in COVID-19, and provides a direct view on the temporal evolution of SARS-CoV-2 infection as proxy for its immunological stage. This might harbor prognostic value, outside the scope of present analysis. Finally, chest CT allows the detection of other medical conditions with similar symptoms as COVID-19 such as bacterial pneumoniae, pleural effusion, lung cancer, pneumothorax and cardiac failure. In conclusion, our data provide clear guidance for rational use of chest CT in COVID-19 triage during a pandemic phase. CT with structured CO-RADS scoring has strong diagnostic power for COVID-19 pneumonia. In symptomatic patients, a CO-RADS ≥ 3 serv...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-